Monitor for FDA regulatory updates on Anaphylm (dibutepinephrine) sublingual film, which is the key near-term catalyst referenced in the filing. The board appointment itself is routine and does not change the investment thesis.
Price Chart
Executive Summary
Aquestive Therapeutics appointed Richard J. Daly to its Board of Directors, effective October 14, 2026, expanding the board from seven to eight members. Mr. Daly brings extensive commercial and operating experience from senior roles at AstraZeneca, Takeda, and Catalyst Pharmaceuticals, which management highlighted as valuable for the potential launch of Anaphylm. This is a routine board appointment with no financial impact.
Key Facts
- Richard J. Daly elected to the Board of Directors, effective October 14, 2026
- Board expanded from seven to eight directors; seven of eight are independent
- Mr. Daly will receive an initial award of 57,000 stock options under the 2018 Equity Incentive Plan
- Mr. Daly has over 30 years of life sciences leadership experience including CEO of Catalyst Pharmaceuticals
- Appointment is part of preparations for potential launch of Anaphylm (dibutepinephrine) sublingual film
Financial Impact
No material financial impact; standard director compensation with 57,000 stock option grant
Risk Factors
- Anaphylm may not receive FDA approval
- Commercial launch execution risks if approved
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001398733-26-000052 |
| Document: a20260921newboardmember-.htm | 0001398733-26-000052 |
| Document: 0001398733-26-000052-index-headers.html | 0001398733-26-000052 |
| Document: 0001398733-26-000052-index.html | 0001398733-26-000052 |
| Document: 0001398733-26-000052.txt | 0001398733-26-000052 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $4.07 (+0.25%) |
Oct 15, 2026 12d ago | Press Release | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $4.07 (+0.25%) |
Oct 14, 2026 13d ago | 8-K | $4.61 $4.08 | ▼ −11.50% | ▼ −11.95% | $4.07 (−11.71%) |
Oct 7, 2026 20d ago | SC 13G | $4.62 $4.61 | ▼ −0.22% | ▲ +0.76% | $4.07 (−11.90%) |
Oct 7, 2026 20d ago | SC 13G/A | $4.62 $4.61 | ▲ +0.22% | ▼ −0.76% | $4.07 (+11.90%) |
Sep 29, 2026 28d ago | 8-K | $4.67 $4.61 | ▼ −1.28% | ▼ −3.23% | $4.07 (−12.85%) |
Sep 25, 2026 4w ago | 8-K | $4.68 $4.55 | ▼ −2.78% | ▼ −2.56% | $4.07 (−13.03%) |
Sep 17, 2026 5w ago | 8-K | $4.66 $4.82 | ▲ +3.43% | ▲ +2.83% | $4.07 (−12.66%) |
Sep 16, 2026 5w ago | Insider Cluster | $4.82 $4.70 | ▼ −2.49% | ▼ −5.05% | $4.07 (−15.56%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.29 $4.80 | ▲ +11.89% | ▲ +13.08% | $4.07 (−5.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers